36C24219R0014-150.pdf

D.9 WORKLOAD HISTORY

Workload Estimates:

As of August 31, 2019, enrollment at the main CBOC and satellite outreach clinic within Erie County is approximately 1,847 and 856, respectively.

The following is a listing of estimated numbers of veterans residing in Erie, Cattaraugus, and Wyoming Counties as of 09/30/2019 according to the following website: http://www1.va.gov/vetdata/Veteran_Population.asp

Type User & Enrollee Erie County

Cattaraugus

County

Wyoming

County TOTAL

Current Users/Enrollees:

2018 P1-6 Users 6,639 70 154 6,863

2018 P1-6 Enrollees 9,025 96 202 9,323

Projected Enrollees:

2019 P1-6 Enrollees 18,927 2,488 933 22,349

2020 P1-6 Enrollees 18,880 2,498 927 22,305

2021 P1-6 Enrollees 18,804 2,506 918 22,228

2022 P1-6 Enrollees 18,708 2,514 908 22,129

2023 P1-6 Enrollees 18,594 2,519 898 22,011

All these veterans are not actually “enrolled” at VA or a CBOC.

There are eight (8) Priority Groups to which veterans may be assigned after processing. All applications for all eight (8) groups are input into VISTA by the CBOC for reporting and accountability purposes, but those veterans in Priority Group 8, who applied after 1/17/03, are ineligible and will not receive services by the Contractor. Veterans are not "assigned" to a CBOC but may choose either to be seen at VAWNYHS or to be enrolled in a CBOC. The VAWNYHS will notify eligible veterans about the availability of the Lackawanna/S. West Seneca CBOC and satellite outreach clinic in Springville and the services to be provided there. The Government estimates that each patient will make 4.12 visits per contract year to their respective site.

The numbers of veterans residing in the counties identified above and estimated numbers of visits per patient per year as stated above are estimates only and are to be used for information purposes only. The VA in no way guarantees the accuracy of the estimates. The Contractor fully understands and agrees that costs for any additional visits above the estimated average visits per unique veteran patient and all primary care services as specified in the Performance Work Statement (PWS) are borne by the contractor and is included in the capitation rates agreed to by the contractor in the Schedule of Services/Price/Costs section.

Patients have the right to receive primary care other than from the VAWNYHS or a VAWNYHS CBOC. The VA, however, encourages patients to have only one primary care provider; and it is the VAWNYHS’s expectation that the patient is seen at the main CBOC or satellite outreach clinic at least once per twelve (12) month period or as often as deemed clinically appropriate by the veteran’s VHA CBOC primary care provider (for further guidance, please also refer to VHA Directive 2009-038 dated August 25, 2009, which is available at http://vaww1.va.gov/vhapublications/ViewPublication.asp?pub_ID=2058).

Statistical Information:

The Erie County CBOC has a main CBOC facility currently located in Lackawanna, NY, USA, that has been in operation since approximately July 2000. The outreach clinic facility located in Springville, NY, USA has been in operation since approximately January 2009. The following is the most recent statistical information for services provided for the Erie County CBOC sites for the period 10/01/2018 - 09/30/2019 (FY 19). Please note, all data provided is for informational purposes only and does not represent any guarantee.

http://www1.va.gov/vetdata/Veteran_Population.asp http://www1.va.gov/vetdata/Veteran_Population.asp http://vaww1.va.gov/vhapublications/ViewPublication.asp?pub_ID=2058 http://vaww1.va.gov/vhapublications/ViewPublication.asp?pub_ID=2058

For Reference:

• Unduplicated Encounters: An unduplicated count of clinic stops where duplicates have been removed. A duplicate clinic stop occurs when a patient makes more than one of the same type of PRIMARY clinic stop at the same substation on the same day.

• Encounter: An encounter is a professional contact between a patient and a practitioner vested with primary responsibility for diagnosing, evaluating, and/or treating the patient’s condition. Encounters occur in both the outpatient and inpatient setting. Contact can include face-to-face interactions or those accomplished via telemedicine technology).

FY 19 Visits & Encounters per Unique Outpt by VISN (Includes both sites – main and satellite)

FY 19 Age & Sex Distribution (Includes both sites – main and satellite)

FY 19 Most Frequent ICD Diagnoses (Includes both sites – main and satellite)

Estimated Annual Medication & Immunization Utilization – Main Facility*

Item Qty

ALBUTEROL 3 MG/IPRATROPIUM 0.5MG/3ML INHL (DUONEB) (3 mL) 3MG/0.5MG PER 3ML 28

ALBUTEROL SOLN 0.083% (PREMIX) 2.5MG/3ML (PROVENTIL) (3 mL) SOLN INHL 32

ARIPIPRAZOLE SA (400MG/VIAL) (ABILIFY MAINTENA) INJ SUSP 4

cefTRIAXone VIAL (ROCEPHIN) 250 mg INJ POWDER 4 cloNIDine (CATAPRES) 0.1 mg TAB 28

COLLAGENASE 250 UINTS/GM TOP (SANTYL) (30 g) OINT TOP TUBE 4

CYANOCOBALAMIN (Vitamin B12) 1000 mcg/1 mL (1 mL) INJ VIAL 48

INFLUENZA VACC,TRIVAL,ADJ (PF) (FLUAD) INJ 480

INFLUENZA VACCINE,QUAD(PF) SYR (AFLURIA) (0.5 mL) INJ SYRINGE 260

KETOROLAC TROMETHAMINE (TORODOL) 15 mg/1 mL (1 mL) INJ SYRINGE 16

LIDOCAINE 1% (XYLOCAINE) (20 mL) INJ VIAL 1 methylPREDNISOLONE NA SUCCINATE 125MG (SOLU-MEDROL) 62.5 mg/1 mL (2 mL) INJ VIAL ACT-O-VIAL 20

NALOXONE (EQV-NARCAN) (NARCAN) 0.4 mg/1 mL (1 mL) INJ VIAL 16

PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (PREVNAR 13 VACCINE) (0.5 mL) INJ SYRINGE 88

PNEUMOCOCCAL 23-VALENT VACCINE (PNEUMOVAX-23) (0.5 mL) INJ SYRINGE 484

PNEUMOCOCCAL 23-VALENT VACCINE (PNEUMOVAX-23) INJ 40

TETANUS/DIPHTHERIA/PERTUSSIS VACCINE ((Tdap) (BOOSTRIX)) (0.5 mL) INJ SYRINGE 128

TROPICAMIDE 1% (MYDRIACYL) 1 drop/0.05 mL (15 mL) SOLN OPH 8

TUBERCULIN, PPD (APLISOL) 5 unit/0.1 mL INJ SOLN 124

ZOSTER VACCINE RECOMBINANT (SHINGRIX) (0.5 mL) INJ VIAL (NOTE: This may be artificially low due to shortage of the vaccination) 164

*Note: This information is provided for informational purposes only – patient care needs may dictate a requirement for other medications or immunizations, which will be the Contractor’s responsibility. The Contractor is responsible for all medications and immunizations that are to be administered in clinic.

Estimated Annual Medication & Immunization Utilization – Satellite Outreach Clinic*

ALBUTEROL 3 MG/IPRATROPIUM 0.5MG/3ML INHL (DUONEB) (3 mL) 3MG/0.5MG PER 3ML 12

ALBUTEROL SOLN 0.083% (PREMIX) 2.5MG/3ML (PROVENTIL) (3 mL) SOLN INHL 8

ARIPIPRAZOLE SA (400MG/VIAL) (ABILIFY MAINTENA) INJ SUSP 3

cefTRIAXone VIAL (ROCEPHIN) 250 mg INJ POWDER 8 cloNIDine (CATAPRES) 0.1 mg TAB 16

CYANOCOBALAMIN (Vitamin B12) 1000 mcg/1 mL (1 mL) INJ VIAL 196

DIPHTHERIA (2 UNITS)/TETANUS (5 UNITS) TOXOID ADSORBED (TENIVAC (Td)) (0.5 mL) INJ SYRINGE 92

HALOPERIDOL DECANOATE (HALDOL) 100 mg/1 mL (1 mL) VIAL 32

HEPATITIS A 720 EL U/HEPATITIS B 20 MCG VACCINE (TWINRIX) (1 mL) INJ SYRINGE 12

HEPATITIS B VACCINE (RECOMBINANT) (ENGERIX-B) 20 mcg/1 mL (1 mL) INJ VIAL 28

INFLUENZA VACC,TRIVAL,ADJ (PF) (FLUAD) INJ 320

INFLUENZA VACCINE,QUAD(PF) SYR (AFLURIA) (0.5 mL) INJ SYRINGE 192

LIDOCAINE 1% (XYLOCAINE) (20 mL) INJ VIAL 4

NALOXONE (EQV-NARCAN) (NARCAN) 0.4 mg/1 mL (1 mL) INJ VIAL 16

NALOXONE NASAL SLN 4 MG SPRAY (Narcan) 4 mg SOLN SPRAY,NASAL 4

PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (PREVNAR 13 VACCINE) (0.5 mL) INJ SYRINGE 193

PNEUMOCOCCAL 23-VALENT VACCINE (PNEUMOVAX-23) INJ 120

RISPERIDONE MICROSPHERE 50 MG (RISPERDAL CONSTA) INJ VIAL SUSPENSION 20

TETANUS/DIPHTHERIA/PERTUSSIS VACCINE ((Tdap) (BOOSTRIX)) (0.5 mL) INJ SYRINGE 72

TUBERCULIN, PPD (APLISOL) 5 unit/0.1 mL INJ SOLN 68

ZOSTER VACCINE RECOMBINANT (SHINGRIX) (0.5 mL) INJ VIAL (NOTE: This may be artificially low due to shortage of the vaccination)

*Note: This information is provided for informational purposes only – patient care needs may dictate a requirement for other medications or immunizations, which will be the Contractor’s responsibility. The Contractor is responsible for all medications and immunizations that are to be administered in clinic.